Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02237677 · ClinicalTrials.gov registry record
CB1 Receptor PET Imaging Reveals Gender Differences in PTSD
A clinical trial, sponsored by NYU Langone Health.
- Terminated
- Registry status
- 36
- Enrollment target
NCT02237677 is a clinical trial that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 36 participants.
The verdict
NCT02237677 was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- 36 participants
- Enrollment target
Study Summary
The objective of the proposed translational study is to test a model, based upon basic science studies, exploring multisystem impairments in PTSD including endocannabinoid (eCB) and glucocorticoids in the modulation of fear memories by examining the cannabinoid type 1 (CB1) receptor in a PTSD fear circuit as well as glucocorticoid function. The investigators propose that impaired eCB signaling in PTSD resulting in the maladaptive neurobehavioral response to the stressor is associated with an upregulation of the CB1 receptors and insufficient glucocorticoid signaling.
Interventions
- OTHER Positron emission tomography (PET) imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-06 |
| Est. Completion | 2016-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02237677
The ClinicalTrials.gov registry entry for NCT02237677 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Positron emission tomography (PET) imaging is the first listed.
NCT02237677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02237677 about?
NCT02237677 is a clinical study titled "CB1 Receptor PET Imaging Reveals Gender Differences in PTSD". The objective of the proposed translational study is to test a model, based upon basic science studies, exploring multisystem impairments in PTSD including endocannabinoid (eCB) and glucocorticoids in the modulation of fear memories by examining the cannabinoid type 1 (CB1) receptor in a PTSD fear c...
What is the current status of trial NCT02237677?
This trial is currently terminated. The enrollment target is 36 participants. The study started on 2012-06. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02237677?
The interventions under investigation include: Positron emission tomography (PET) imaging (OTHER).
Who is sponsoring clinical trial NCT02237677?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.